Problems › We Keep Discounting to Win Deals › B2B SaaS
Routine discounting is usually a proof problem and an incentive problem, and almost never a list-price problem. B2B SaaS companies carry a specific bind here — growth has fallen from 42% to 32% while 60% of revenue sits in the segment with the worst economics. Until that is priced, net revenue retention will keep moving for reasons nobody can attribute, and the debate about discount distribution will stay a matter of opinion.
Routine discounting is usually a proof problem and an incentive problem, and almost never a list-price problem. B2B SaaS companies carry a specific bind here — growth has fallen from 42% to 32% while 60% of revenue sits in the segment with the worst economics. Until that is priced, net revenue retention will keep moving for reasons nobody can attribute, and the debate about discount distribution will stay a matter of opinion.
When discounting becomes normal, the ACV has effectively been reset to the discounted level and the published price is decoration. That has a cost beyond the margin: it tells the market what you actually charge, and it is very hard to reverse without damaging net revenue retention.
The causes are consistent. The value is not proven along the land-and-expand path, so price becomes the only variable left to discuss. Or the sales incentive rewards new ARR over margin, in which case discounting is exactly the rational behaviour. Or discretion is unlimited, and unlimited discretion is always used.
The diagnostic is the distribution. If discounts cluster at the end of a quarter or at particular individuals, the cause is incentive and authority, not price.
These three together are the signature. One on its own usually points somewhere else.
✓ Discount requests and ACV approvals spike in the final weeks of the quarter while CAC payback remains flat.
✓ ACV realized on comparable deals varies widely between reps even inside the same segment.
✓ Reps request ACV reductions instead of support building net revenue retention cases or proof points.
The move that usually makes it worse. Lowering target ACV or published pricing to reflect reality, which resets the anchor and produces the same discount off the new number within two quarters.
It is for you if you run or finance a B2B SaaS company and discounts spike at period end. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a B2B SaaS company. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is TechNova Solutions, a sample company profile used for testing rather than a customer — $45M ARR, 280 engineers.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn the 11-week implementation backlog into 50 reusable modules that lift services gross margin from 41 % to 55 % while preserving 23 % win rate.
| Investment required | $3.0-4.2 M total over 36 months |
| Expected return | Base case 3.8× cash-on-cash within 36 months |
| Revenue, year 1 | $47.8-49.2 M ARR |
| Revenue, year 2 | $51.5-54.0 M ARR |
| Revenue, year 3 | $56.0-60.0 M ARR |
| Exit criteria | Strategy abandoned if, by Month 12, template-able rule rate remains below 40 % OR if NRR of pilot cohort falls below 85 %; capital reallocated to Segment 2 analytics bolt-on. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Pricing & Revenue Optimization, one of 29 engagements the platform runs. For B2B SaaS companies it works through net revenue retention, CAC payback, ACV by segment and gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Cap the discretion and pay on margin rather than on revenue. Discounting is a rational response to a quota measured in revenue with unlimited price authority attached.
No — as a deliberate, structured exchange for something you want, such as term, volume or a reference. As a reflex at the close of a negotiation, it is margin given away for nothing.
Move them at renewal with notice and a reason, and accept that some will leave. The alternative is a permanent two-tier price the rest of the market eventually discovers.
Materially, yes. Growth has fallen from 42% to 32% while 60% of revenue sits in the segment with the worst economics — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are net revenue retention, CAC payback, ACV by segment, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on net revenue retention and CAC payback. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית